For patients with EGFR-mutated NSCLC, treatment options in the frontline include osimertinib monotherapy, amivantamab with ...

During a live event, Xiuning Le, MD, PhD, discussed clinical trials of supportive care for infusion reaction and skin rash ...

That’s it for 2025’s Q1 clinical trials round-up. If you have a study that could fit the bill for our next column, please ...

UB medicinal chemist David Heppner has received the 2025 Philip S. Portoghese Lectureship Award from the American Chemical ...

Bispecific Antibodies in Hematologic and Solid Tumors: Current Landscape and Therapeutic Advances Liquid biopsy encompasses a variety of molecular approaches to detect circulating tumor DNA (ctDNA) ...

Adagrasib shows early signs of activity and tolerability in patients with STK11/KRAS G12C–mutated non–small cell lung cancer. The ORR appeared numerically higher in patients without KEAP1 comutations ...

Explore the latest NSCLC new treatments in development, including candidates aimed at tackling hard-to-treat, late-stage lung ...

Boehringer Ingelheim has already filed for approval of zongertinib having gained priority review designation from the FDA. Image credit: Shutterstock / Tada Images. Boehringer Ingelheim’s drug ...

In Cohort 1, participants must not have received any prior systemic therapy and will receive SC amivantamab and oral lazertinib; in Cohort 2, participants must have had disease progression after ...

Yonsei University Hospital Cancer Center, Seoul, Republic of Korea.